Q-omics provides the consensus-scored WDR82 profile across patient tissues and cancer cell-line models. WDR82 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WDR82 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, WDR82 protein abundance shows 26,210 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where WDR82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR82 survival associations across molecular data types. WDR82 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR82 RNA expression–survival associations across cancer types. High WDR82 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UCEC, BRCA, HNSC and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WDR82 RNA expression.
This table summarizes WDR82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR82 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, STAD, CHOL and READ. The LIHC box plot shows higher WDR82 RNA expression in tumor versus normal tissue (log2 FC = +0.759, t-test p < 0.001).
This table shows molecular features associated with WDR82 in patient tissues and cancer cell lines. In patient samples, WDR82 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
